What question did this study set out to answer?

This research aims to compare the effectiveness of adalimumab and infliximab for achieving sustained remission in ulcerative colitis patients.

February 25, 2026Open Access

Adalimumab and infliximab are equally efficient in achieving sustained remission in ulcerative colitis but infliximab is superior in severe disease—a retrospective observational study

Puntos clave

This research aims to compare the effectiveness of adalimumab and infliximab for achieving sustained remission in ulcerative colitis patients.
Retrospective analysis of bio-naive patients with ulcerative colitis
Comparison of remission rates between adalimumab and infliximab
Evaluation of remission induction specifically in severe disease cases
Both adalimumab and infliximab achieved similar long-term remission rates
Infliximab showed superior effectiveness in inducing remission in severe cases

Resumen

Adalimumab and infliximab achieved similar rates of long-term remission in bio-naive patients with ulcerative colitis. However, infliximab was superior in induction of remission and in patients with severe disease.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo